Page 14 - 《中国药房》2023年17期

[ 9 ] ROHRER M，BAUER H，MINTOROVITCH J，et al. new macrocyclic gadolinium chelate with high T1 relaxi-
Comparison of magnetic properties of MRI contrast media vity[J]. Invest Radiol，2019，54（8）：475-484.
solutions at different magnetic field strengths[J]. Invest [20] LOEVNER L A，KOLUMBAN B，HUTÓCZKI G，et al.
Radiol，2005，40（11）：715-724. Efficacy and safety of gadopiclenol for contrast-enhanced
[10] 段二月，马建功，程鹏. 钆类造影剂的研究进展[J]. 大学 MRI of the central nervous system：the PICTURE rando-
化学，2016，31（7）：1-13. mized clinical trial[J]. Invest Radiol，2023，58（5）：
[11] Radiology European Society of Urogenital. ESUR guide‐ 307-313.
lines on contrast agents[M]. Vienna：ESUR Guidelines on [21] 中华医学会放射学分会质量控制与安全管理专业委员
Contrast Agents，2018：6-35. 会 . 肾病患者静脉注射钆对比剂应用中国专家共识[J].
[12] RONG D L，HE B J，TANG W J，et al. Comparison of 中华放射学杂志，2022，56（3）：221-230.
gadobenate-enhanced MRI and gadoxetate-enhanced MRI [22] BEHZADI A H，ZHAO Y Z，FAROOQ Z，et al. Imme-
for hepatocellular carcinoma detection using LI-RADS diate allergic reactions to gadolinium-based contrast agents：
version 2018：a prospective intraindividual randomized a systematic review and meta-analysis[J]. Radiology，
study[J]. AJR Am J Roentgenol，2022，218（4）：687-698. 2018，286（2）：731.
[13] SOULEZ G，BLOOMGARDEN D C，ROFSKY N M， [23] 耿雯瑾，赵月婷，曾贞，等. 肾源性系统性纤维化1例[J].
et al. Prospective cohort study of nephrogenic systemic 中国皮肤性病学杂志，2020，34（10）：1170-1172.
fibrosis in patients with stage 3-5 chronic kidney disease [24] MCDONALD R J，MCDONALD J S，KALLMES D F，
undergoing MRI with injected gadobenate dimeglumine et al. Intracranial gadolinium deposition after contrast-
or gadoteridol[J]. AJR Am J Roentgenol，2015，205（3）： enhanced MR imaging[J]. Radiology，2015，275（3）：
469-478. 772-782.
[14] WOOLEN S A，SHANKAR P R，GAGNIER J J，et al. [25] MURATA N，GONZALEZ-CUYAR L F，MURATA K，
Risk of nephrogenic systemic fibrosis in patients with et al. Macrocyclic and other non-group 1 gadolinium con‐
stage 4 or 5 chronic kidney disease receiving a group Ⅱ trast agents deposit low levels of gadolinium in brain and
gadolinium-based contrast agent：a systematic review and bone tissue：preliminary results from 9 patients with nor‐
meta-analysis[J]. JAMA Intern Med，2020，180（2）： mal renal function[J]. Invest Radiol，2016，51（7）：
223-230. 447-453.
[15] ATTARI H，CAO Y，ELMHOLDT T R，et al. A systematic [26] KANDA T，FUKUSATO T，MATSUDA M，et al.
review of 639 patients with biopsy-confirmed nephrogenic Gadolinium-based contrast agent accumulates in the brain
systemic fibrosis[J]. Radiology，2019，292（2）：376-386. even in subjects without severe renal dysfunction：evalua‐
[16] STAREKOVA J，BRUCE R J，SADOWSKI E A，et al. No tion of autopsy brain specimens with inductively coupled
cases of nephrogenic systemic fibrosis after administration plasma mass spectroscopy[J]. Radiology，2015，276（1）：
of gadoxetic acid[J]. Radiology，2020，297（3）：556-562. 228-232.
[17] TSENG T Y，TSENG J H，HUANG B S，et al. Risk of [27] MCDONALD R J，MCDONALD J S，DAI D Y，et al.
nephrogenic systemic fibrosis in patients with impaired re‐ Comparison of gadolinium concentrations within multiple
nal function undergoing fixed-dose gadoxetic acid- rat organs after intravenous administration of linear versus
enhanced magnetic resonance imaging[J]. Abdom Radiol， macrocyclic gadolinium chelates[J]. Radiology，2017，285
2021，46（8）：3995-4001. （2）：536-545.
[18] ROBERT P，VIVES V，GRINDEL A L，et al. Contrast-to- [28] JOST G，FRENZEL T，BOYKEN J，et al. Long-term ex‐
dose relationship of gadopiclenol，an MRI macrocyclic cretion of gadolinium-based contrast agents：linear versus
gadolinium-based contrast agent，compared with gado- macrocyclic agents in an experimental rat model[J]. Radi‐
terate，gadobenate，and gadobutrol in a rat brain tumor ology，2019，290（2）：340-348.
model[J]. Radiology，2020，294（1）：117-126. （收稿日期：2023-06-09 修回日期：2023-07-17）
[19] ROBIC C，PORT M，ROUSSEAUX O，et al. Physico‐ （编辑：刘明伟）
chemical and pharmacokinetic profiles of gadopiclenol：a

· 2056 · China Pharmacy 2023 Vol. 34 No. 17 中国药房 2023年第34卷第17期